Therapy of community-acquired acute bacterial meningitis: The clock is running

Expert Opinion on Pharmacotherapy

Volumn 10, Issue 16, 2009, Pages 2609-2623

  Klein, M ^a   Pfister, H W ^a   Leib, S L ^b   Koedel, U ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

Antibiotic therapy; Bacterial; CNS infection; Meningitis; Neisseria meningitidis; Streptococcus pneumoniae

Indexed keywords

AMINOGLYCOSIDE; AMOXICILLIN; AMPICILLIN; ANTIBIOTIC AGENT; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CHLORAMPHENICOL; CIPROFLOXACIN; COTRIMOXAZOLE; DAPTOMYCIN; DEXAMETHASONE; FLUCLOXACILLIN; FOSFOMYCIN; GENTAMICIN; HEPARIN; LINEZOLID; MEROPENEM; METRONIDAZOLE; MOXIFLOXACIN; NIMODIPINE; PENICILLIN G; PLACEBO; QUINOLONE DERIVATIVE; RIFAMPICIN; VANCOMYCIN;

ADJUVANT THERAPY; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; BACTERIAL MENINGITIS; BLEEDING; BLOOD CULTURE; BRAIN EDEMA; BRAIN HEMORRHAGE; BRAIN INFARCTION; BRAIN VASOSPASM; CAVERNOUS SINUS THROMBOSIS; CEREBRAL SINUS THROMBOSIS; CEREBROSPINAL FLUID ANALYSIS; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; EPIDEMIC MENINGITIS; FEVER; HAEMOPHILUS MENINGITIS; HUMAN; HYDROCEPHALUS; HYPOTENSION; LABORATORY TEST; LISTERIOSIS; LUMBAR PUNCTURE; MENINGOCOCCOSIS; MENTAL DISEASE; MONOTHERAPY; MUSCLE STIFFNESS; NONHUMAN; PNEUMOCOCCAL MENINGITIS; REVIEW; SINGLE DRUG DOSE; STAPHYLOCOCCUS AUREUS MENINGITIS; TREATMENT DURATION; VASCULAR DISEASE;

ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; DEXAMETHASONE; HUMANS; MENINGITIS, BACTERIAL; MICROBIAL SENSITIVITY TESTS;

EID: 72949123206     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560903277210     Document Type: Review

References (99)

1. World Health Organization. The global burden of disease: 2004 update. World Health Organisation; 2008
2. Brouwer MC, Van De Beek D, Heckenberg SG, et al. Community-acquired listeria monocytogenes meningitis in adults. Clin Infect Dis 2006;43(10):1233-1238 (Pubitemid 44706446)
3. Van De Beek D, De Gans J, McIntyre P, Prasad K. Corticosteroids for acute bacterial meningitis. Cochrane Database Syst Rev 2007;1:CD004405
4. Scarborough M, Gordon SB, Whitty CJ, et al. Corticosteroids for bacterial meningitis in adults in sub-Saharan Africa. N Engl J Med 2007;357(24):2441-2450
5. Auburtin M, Wolff M, Charpentier J, et al. Detrimental role of delayed antibiotic administration and penicillin-nonsusceptible strains in adult intensive care unit patients with pneumococcal meningitis: the PNEUMOREA prospective multicenter study. Crit Care Med 2006;34(11):2758-2765
6. Proulx N, Frechette D, Toye B, et al. Delays in the administration of antibiotics are associated with mortality from adult acute bacterial meningitis. QJM 2005;98(4):291-298
7. Van De Beek D, De Gans J, Spanjaard L, et al. Clinical features and prognostic factors in adults with bacterial meningitis. N Engl J Med 2004;351(18):1849-1859
8. Heckenberg SG, De Gans J, Brouwer MC, et al. Clinical features, outcome, and meningococcal genotype in 258 adults with meningococcal meningitis: a prospective cohort study. Medicine 2008;87(4):185-192
9. Kastenbauer S, Pfister HW. Pneumococcal meningitis in adults: spectrum of complications and prognostic factors in a series of 87 cases. Brain 2003;126(Pt 5):1015-1025
10. Attia J, Hatala R, Cook DJ, Wong JG. The rational clinical examination. Does this adult patient have acute meningitis? JAMA 1999;282(2):175-181
11. Thomas KE, Hasbun R, Jekel J, Quagliarello VJ. The diagnostic accuracy of Kernig's sign, Brudzinski's sign, and nuchal rigidity in adults with suspected meningitis. Clin Infect Dis 2002;35(1):46-52
12. Joffe AR. Lumbar puncture and brain herniation in acute bacterial meningitis: a review. J Intensive Care Med 2007;22(4):194-207
13. Winkler F, Kastenbauer S, Yousry TA, et al Discrepancies between brain CT imaging and severely raised intracranial pressure proven by ventriculostomy in adults with pneumococcal meningitis. J Neurol 2002;249(9):1292-1297
14. Kastenbauer S, Winkler F, Pfister HW. Cranial CT before lumbar puncture in suspected meningitis. N Engl J Med 2002;346(16):1248-1251
15. Durand ML, Calderwood SB, Weber DJ, et al. Acute bacterial meningitis in adults. A review of 493 episodes. N Engl J Med 1993;328(1):21-28
16. Hussein AS, Shafran SD. Acute bacterial meningitis in adults. A 12-year review. Medicine 2000;79(6):360-368
17. Nigrovic LE, Malley R, Macias CG, et al. Effect of antibiotic pretreatment on cerebrospinal fluid profiles of children with bacterial meningitis. Pediatrics 2008;122(4):726-730
18. Prat C, Dominguez J, Rodrigo C, et al. Use of quantitative and semiquantitative procalcitonin measurements to identify children with sepsis and meningitis. Eur J Clin Microbiol Infect Dis 2004;23(2):136-138
19. Viallon A, Guyomarc'h P, Guyomarc'h S, et al. Decrease in serum procalcitonin levels over time during treatment of acute bacterial meningitis. Crit Care 2005;9(4): R344-50
20. Dubos F, Moulin F, Gajdos V, et al. Serum procalcitonin and other biologic markers to distinguish between bacterial and aseptic meningitis. J Pediatr 2006;149(1):72-76
21. Dubos F, Korczowski B, Aygun DA, et al. Serum procalcitonin level and other biological markers to distinguish between bacterial and aseptic meningitis in children: a European multicenter case cohort study. Arch Pediatr Adolesc Med 2008;162(12):1157-1163
22. Schwarz S, Bertram M, Schwab S, et al. Serum procalcitonin levels in bacterial and abacterial meningitis. Crit Care Med 2000;28(6):1828-1832
23. Welinder-Olsson C, Dotevall L, Hogevik H, et al. Comparison of broad-range bacterial PCR and culture of cerebrospinal fluid for diagnosis of community-acquired bacterial meningitis. Clin Microbiol Infect 2007;13(9):879-886
24. Pfister HW. Meningitis: Klinik - differentialdiagnose - pathophysiologie - therapie. W Kohlhammer GmbH; 2002
25. Rai GP, Zachariah K, Sharma R, et al. Pneumococcal antigen detection in cerebrospinal fluid: a comparative study on counter immunoelectrophoresis, latex agglutination and coagglutination. Comp Immunol Microbiol Infect Dis 2003;26(4):261-267
26. Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 2004;39(9):1267-1284
27. Boving MK, Pedersen LN, Moller JK. Eight-plex PCR and liquid array detection of bacterial and viral pathogens in cerebrospinal fluid from patients with suspected meningitis. J Clin Microbiol 2009;47(4):908-913
28. Diggle MA, Clarke SC. Molecular methods for the detection and characterization of Neisseria meningitidis. Expert Rev Mol Diagn 2006;6(1):79-87
29. Fuglsang-Damgaard D, Pedersen G, Schonheyder HC. Positive blood cultures and diagnosis of bacterial meningitis in cases with negative culture of cerebrospinal fluid. Scand J Infect Dis 2008;40(3):229-233
30. Chaudhuri A, Martin PM, Kennedy PG, et al. EFNS guideline on the management of community-acquired bacterial meningitis: report of an EFNS Task Force on acute bacterial meningitis in older children and adults. Eur J Neurol 2008;15(7):649-659
31. World Health Organization. Standardized treatment of bacterial meningitis in Adrica in epidemic and non-epidemic situations. World Health Organisation; 2007
32. Prasad K, Kumar A, Gupta PK, Singhal T. Third generation cephalosporins versus conventional antibiotics for treating acute bacterial meningitis. Cochrane Database Syst Rev 2007;4:CD001832
33. Reinert R, Reinert S, van der Linden M, et al. Antimicrobial susceptibility of Streptococcus pneumoniae in eight European countries from 2001 to 2003. Antimicrob Agents Chemother 2005;49(7):2903-2913
34. Ricard JD, Wolff M, Lacherade JC, et al. Levels of vancomycin in cerebrospinal fluid of adult patients receiving adjunctive corticosteroids to treat pneumococcal meningitis: a prospective multicenter observational study. Clin Infect Dis 2007;44(2):250-255
35. Martinez-Lacasa J, Cabellos C, Martos A, et al. Experimental study of the efficacy of vancomycin, rifampicin and dexamethasone in the therapy of pneumococcal meningitis. J Antimicrob Chemother 2002;49(3):507-513
36. Lee H, Song JH, Kim SW, et al. Evaluation of a triple-drug combination for treatment of experimental multidrug-resistant pneumococcal meningitis. Int J Antimicrob Agents 2004;23(3):307-310 (Pubitemid 38283603)
37. Ribes S, Taberner F, Domenech A, et al. Evaluation of ceftriaxone, vancomycin and rifampicin alone and combined in an experimental model of meningitis caused by highly cephalosporin-resistant Streptococcus pneumoniae ATCC 51916. J Antimicrob Chemother 2005;56(5):979-982
38. Tubau F, Linares J, Ardanuy C, et al. In vitro bactericide activity of different antibiotic combinations to Streptococcus pneumoniae resistant to penicillin and cefotaxime. Enferm Infecc Microbiol Clin 1996;14(10):590-595
39. Scarborough M, Thwaites GE. The diagnosis and management of acute bacterial meningitis in resource-poor settings. Lancet Neurol 2008;7(7):637-648
40. Mitja O, Pigrau C, Ruiz I, et al. Predictors of mortality and impact of aminoglycosides on outcome in listeriosis in a retrospective cohort study. J Antimicrob Chemother 2009;64(2):416-423
41. Rupprecht TA, Pfister HW. Clinical experience with linezolid for the treatment of central nervous system infections. Eur J Neurol 2005;12(7):536-542
42. Higa T, Tasaka T, Kubo Y, et al. Successful treatment of meningoencephalitis caused by methicillin-resistant Staphylococcus aureus with intravenous linezolid in an allogeneic cord blood stem cell transplant recipient. Scand J Infect Dis 2008;40(11-12):990-992
43. Mizell KN, Carter JE. Vancomycin-resistant Enterococcus faecium meningitis successfully treated with linezolid. South Med J 2008;101(5):569-570
44. Nagashima G, Okamoto N, Okuda M, et al. Effect of linezolid against postneurosurgical meningitis caused by methicillin-resistant Staphylococcus epidermidis: case report. J Infect Chemother 2008;14(2):147-150
45. Ntziora F, Falagas ME. Linezolid for the treatment of patients with central nervous system infection. Ann Pharmacother 2007;41(2):296-308
46. Lee DH, Palermo B, Chowdhury M. Successful treatment of methicillin-resistant Staphylococcus aureus meningitis with daptomycin. Clin Infect Dis 2008;47(4):588-590
47. Koster-Rasmussen R, Korshin A, Meyer CN. Antibiotic treatment delay and outcome in acute bacterial meningitis. J Infect 2008;57(6):449-454
48. Cartwright K, Reilly S, White D, Stuart J. Early treatment with parenteral penicillin in meningococcal disease. BMJ 1992;305(6846):143-147
49. Harnden A, Ninis N, Thompson M, et al. Parenteral penicillin for children with meningococcal disease before hospital admission: case-control study. BMJ 2006;332(7553):1295-1298
50. Lu CH, Huang CR, Chang WN, et al. Community-acquired bacterial meningitis in adults: the epidemiology, timing of appropriate antimicrobial therapy, and prognostic factors. Clin Neurol Neurosurg 2002;104(4):352-358
51. Sudarsanam T, Rupali P, Tharyan P, et al. Pre-admission antibiotics for suspected cases of meningococcal disease. Cochrane Database Syst Rev 2008;1: CD005437
52. Singhi P, Kaushal M, Singhi S, Ray P. Seven days vs. 10 days ceftriaxone therapy in bacterial meningitis. J Trop Pediatr 2002;48(5):273-279
53. Lin TY, Chrane DF, Nelson JD, McCracken GH Jr. Seven days of ceftriaxone therapy is as effective as ten days' treatment for bacterial meningitis. JAMA 1985;253(24):3559-3563
54. Pfister HW, Eiffert H, Nau R, et al. Bakterielle (eitrige) Meningoenzephalitis. Leitlinien für Diagnostik und Therapie in der Neurologie der DGN 2008;4
55. Lebel MH, Freij BJ, Syrogiannopoulos GA, et al. Dexamethasone therapy for bacterial meningitis. Results of two double-blind, placebo-controlled trials. N Engl J Med 1988;319(15):964-971
56. Girgis NI, Farid Z, Mikhail IA, et al. Dexamethasone treatment for bacterial meningitis in children and adults. Pediatr Infect Dis J 1989;8(12):848-851
57. Thomas DG. Outcome of paediatric bacterial meningitis 1979-1989. Med J Aust 1992;157(8):519-520
58. Yurkowski PJ, Plaisance KI. Prevention of auditory sequelae in pediatric bacterial meningitis: a meta-analysis. Pharmacotherapy 1993;13(5):494-499
59. McIntyre PB, Berkey CS, King SM, et al. Dexamethasone as adjunctive therapy in bacterial meningitis. A meta-analysis of randomized clinical trials since 1988. JAMA 1997;278(11):925-931
60. De Gans J, Van De Beek D. Dexamethasone in adults with bacterial meningitis. N Engl J Med 2002;347(20):1549-1556
61. Van De Beek D, De Gans J, McIntyre P, Prasad K. Corticosteroids in acute bacterial meningitis. Cochrane Database Syst Rev 2003;3:CD004405
62. Van De Beek D, De Gans J, McIntyre P, Prasad K. Steroids in adults with acute bacterial meningitis: a systematic review. Lancet Infect Dis 2004;4(3):139-143
63. Van De Beek D, De GJ, McIntyre P, Prasad K. Corticosteroids for acute bacterial meningitis. Cochrane Database Syst Rev 2007;CD004405
64. Van De BD. Corticosteroids for acute adult bacterial meningitis. Med Mal Infect 2009;39(7-8):531-538
65. Molyneux EM, Walsh AL, Forsyth H, et al. Dexamethasone treatment in childhood bacterial meningitis in Malawi: a randomised controlled trial. Lancet 2002;360(9328):211-218
66. Nguyen TH, Tran TH, Thwaites G, et al. Dexamethasone in Vietnamese adolescents and adults with bacterial meningitis. N Engl J Med 2007;357(24):2431-2440
67. Pfister HW, Feiden W, Einhaupl KM. Spectrum of complications during bacterial meningitis in adults. Results of a prospective clinical study. Arch Neurol 1993;50(6):575-581
68. Weisfelt M, van de Beek D, Spanjaard L, et al. Clinical features, complications, and outcome in adults with pneumococcal meningitis: a prospective case series. Lancet Neurol 2006;5(2):123-129
69. Kramer AH, Bleck TP. Neurocritical care of patients with central nervous system infections. Curr Infect Dis Rep 2007;9(4):308-314
70. Klein M, Paul R, Angele B, et al. Protein expression pattern in experimental pneumococcal meningitis. Microbes Infect 2006;8(4):974-983
71. Paul R, Koedel U, Pfister HW. Reduction of intracranial pressure by nimodipine in experimental pneumococcal meningitis. Crit Care Med 2000;28(7):2552-2556
72. Hosoglu S, Ceviz A, Kemaloglu MS, et al. Effects of nimodipine on the cerebrovascular and neuronal changes during pneumococcal meningitis in the rat. Acta Microbiol Immunol Hung 1997;44(3):271-279
73. Southwick FS. Septic thrombophlebitis of major dural venous sinuses. Curr Clin Top Infect Dis 1995;15:179-203
74. Zoons E, Weisfelt M, De GJ, et al. Seizures in adults with bacterial meningitis. Neurology 2008;70(22 Pt 2):2109-2115
75. Wu HM, Harcourt BH, Hatcher CP, et al. Emergence of ciprofloxacin- resistant Neisseria meningitidis in North America. N Engl J Med 2009;360(9):886-892
76. Peltola H, Roine I, Fernandez J, et al. Adjuvant glycerol and/or dexamethasone to improve the outcomes of childhood bacterial meningitis: a prospective, randomized, double-blind, placebo-controlled trial. Clin Infect Dis 2007;45(10):1277-1286
77. Sankar J, Singhi P, Bansal A, et al. Role of dexamethasone and oral glycerol in reducing hearing and neurological sequelae in children with bacterial meningitis. Indian Pediatr 2007;44(9):649-656
78. Paul R, Koedel U, Pfister HW. Using knockout mice to study experimental meningitis. Arch Immunol Ther Exp (Warsz) 2003;51(5):315-326
79. Grandgirard D, Schurch C, Cottagnoud P, Leib SL. Prevention of brain injury by the nonbacteriolytic antibiotic daptomycin in experimental pneumococcal meningitis. Antimicrob Agents Chemother 2007;51(6):2173-2178
80. Egermann U, Stanga Z, Ramin A, et al. Combination of daptomycin plus ceftriaxone is more active than vancomycin plus ceftriaxone in experimental meningitis after addition of dexamethasone. Antimicrob Agents Chemother 2009;53(7):3030-3033
81. Lee DH, Palermo B, Chowdhury M. Successful treatment of methicillin-resistant Staphylococcus aureus meningitis with daptomycin. Clin Infect Dis 2008;47(4):588-590
82. Koedel U, Angele B, Rupprecht T, et al. Toll-like receptor 2 participates in mediation of immune response in experimental pneumococcal meningitis. J Immunol 2003;170(1):438-444
83. Klein M, Obermaier B, Angele B, et al. Innate immunity to pneumococcal infection of the central nervous system depends on toll-like receptor (TLR) 2 and TLR4. J Infect Dis 2008;198(7):1028-1036
84. Klein M, Koedel U, Pfister HW. Oxidative stress in pneumococcal meningitis: a future target for adjunctive therapy? Prog Neurobiol 2006;80(6):269-280
85. Klein M, Koedel U, Pfister HW, Kastenbauer S. Meningitis-associated hearing loss: protection by adjunctive antioxidant therapy. Ann Neurol 2003;54(4):451-458
86. Auer M, Pfister LA, Leppert D, et al. Effects of clinically used antioxidants in experimental pneumococcal meningitis. J Infect Dis 2000;182(1):347-350
87. Koedel U, Pfister HW. Protective effect of the antioxidant N-acetyl-L-cysteine in pneumococcal meningitis in the rat. Neurosci Lett 1997;225(1):33-36
88. Ostergaard C, Hoiby N, Konradsen HB, Samuelsson S. Prehospital diagnostic and therapeutic management of otogenic Streptococcus pneumoniae meningitis. Scand J Infect Dis 2006;38(3):172-180
89. Pankey GA, Sabath LD. Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of gram-positive bacterial infections. Clin Infect Dis 2004;38(6):864-870
90. Borg MA, Tiemersma E, Scicluna E, et al. Prevalence of penicillin and erythromycin resistance among invasive Streptococcus pneumoniae isolates reported by laboratories in the southern and eastern Mediterranean region. Clin Microbiol Infect 2009;15(3):232-237
91. Saldias PF, Flores SLJ, Torres MC, et al. Antimicrobial susceptibility of Streptococcus pneumoniae in pediatric and adult population from Santiago, 1997-2003. Rev Med Chil 2005;133(1):42-49
92. Yang F, Xu XG, Yang MJ, et al. Antimicrobial susceptibility and molecular epidemiology of Streptococcus pneumoniae isolated from Shanghai, China. Int J Antimicrob Agents 2008;32(5):386-391
93. Mudhune S, Wamae M. Report on invasive disease and meningitis due to Haemophilus influenzae and Streptococcus pneumonia from the Network for Surveillance of Pneumococcal Disease in the East African Region. Clin Infect Dis 2009;48(Suppl 2): S147-52
94. Siira L, Rantala M, Jalava J, et al. Temporal trends of antimicrobial resistance and clonality of invasive Streptococcus pneumoniae in Finland, 2002-2006. Antimicrob Agents Chemother 2009;35(5)
95. Imohl M, Reinert RR, Van Der LM. New penicillin susceptibility breakpoints for Streptococcus pneumoniae and their effects on susceptibility categorisation in Germany (1992-2008). Int J Antimicrob Agents 2009;34(3):271-273
96. Paraskakis I, Kafetzis DA, Chrisakis A, et al. Serotypes and antimicrobial susceptibilities of 1033 pneumococci isolated from children in Greece during 2001-2004. Clin Microbiol Infect 2006;12(5):490-493
97. Goyal R, Singh NP, Kaur M, Talwar V. Antimicrobial resistance in invasive and colonising Streptococcus pneumoniae in North India. Indian J Med Microbiol 2007;25(3):256-259
98. Jenkins SG, Brown SD, Farrell DJ. Trends in antibacterial resistance among Streptococcus pneumoniae isolated in the USA: update from PROTEKT US Years 1-4. Ann Clin Microbiol Antimicrob 2008;7:1
99. Richter SS, Heilmann KP, Dohrn CL, et al. Changing epidemiology of antimicrobial-resistant Streptococcus pneumoniae in the United States, 2004-2005. Clin Infect Dis 2009;48(3):e23-33